NanoEnTek Inc. (KOSDAQ: 039860) aims to be a leader of creation and innovation in biotechnology, nanotechnology, and information technology.
Fusing the technical expertise of scientists and researchers from the fields of biomedical engineering, bio-MEMS (Micro-Electro-Mechanical Systems), electronics, chemistry, and optics has become a top developer of devices for life science research and point-of-care diagnostics.
Established in 2000 with the aid of venture capital funding, Digital-Bio Technology emerged from the labs of Seoul National University. The brightest minds assembled with a vision to accomplish laboratory functions on a chip, and eventually develop biomedical research and diagnostic devices. Starting with a group of ten, the company has since grown to a family of over sixty members. During this time, the core technology has been nurtured and developed into successful products, leading to thegeneration of income and profits. Upon KOSDAQ listing in 2006, Digital-Bio became NanoEnTek Inc.
NanoEnTek's first mainstream product was the award-winning Countess,the world's first personal cell counter.
Then, JuLI, an easy-to-use live cell analyzer, arrived to break conventional space estrictions and introduce WiFi-based remote viewing. And finally,FREND,a point-of-care testing device that shifts how disease is diagnosed. Any competitor in the worldwide market would be hard pressed to reproduce the unique combination of creativity, innovation, and energy found at NanoEnTek.
We will continue to develop point-of-care diagnostic devices that create new technology with the tenets of the 4P Human Care Culture, to be: Predictive, Preventive, Participatory, and Personalized.
